• About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

Philogen presented “Dekavil (F8-IL10), a novel therapeutic approach for rheumatoid arthritis: ongoing Phase Ib clinical trial results.” at EULAR Rome 2015. Rome (Italy), 10th-13th June, 2015.

by last | Jun 6, 2015 | 2015, Press Releases

Dario Neri and his lab at the ETH Zurich are the recipient of an ERC Advanced Grant for the project titled “Zauberkugel: fulfilling Paul Ehrlich’s dream of therapeutics with activity on demand”. Zurich (Switzerland) June 1, 2015.

by last | Jun 1, 2015 | 2015, Press Releases

Giulio Casi presented “Targeting disease with armed antibodies and small molecule drug conjugates.” at SMI ADC Summit 2015. London (UK), 18th-19th May, 2015.

by last | May 22, 2015 | 2015, Press Releases

Dario Neri presented “Arming tumor-targeting antibodies with cytokine payloads: Emerging clinical results.” at PEGS (Essential Protein Engineering Summit) 2015. Boston (USA), 4th-8th May, 2015.

by last | May 1, 2015 | 2015, Press Releases

Dario Neri presented “Arming tumor-targeting antibodies with cytokine payloads: Emerging clinical results.” at AACR Annual Meeting 2015. Philadelphia (USA), 19th-22nd April, 2015

by last | Apr 19, 2015 | 2015, Press Releases

Mattia Matasci presented “Targeting disease with armed antibodies small molecule drug conjugates” at Antibody Targeted-drug conjugates 2015. Porto (Portugal), 13th-15th April, 2015.

by last | Apr 13, 2015 | 2015, Press Releases

« Older Entries
Next Entries »

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
  • Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
Privacy Policy / Cookie Policy

Contacts

  • Follow

Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch